Similarly, in the PRADO trial of neoadjuvant nivolumab plus ipilimumab, the baseline expression of PD-L1 was correlated with a pathological response rate; that is, for patients with >50% PD-L1-expressing tumor cells, the pathological response rate was 100%; for those with a 1–50% PD-L1-expressing tumor cells, the pathological response rate was 92%, and for those with less than 1% PD-L1-expressing tumor cells, the pathological response rate was 56% [48]. Here, CD274 is linked to neoplasm.